Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Operations (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash from Operations for 4 consecutive years, with 60227000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 191.28% to 60227000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 33327000.0 through Dec 2025, up 40.45% year-over-year, with the annual reading at 33327000.0 for FY2025, 40.45% up from the prior year.
  • Cash from Operations for Q4 2025 was 60227000.0 at Spruce Biosciences, down from 48455000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 48455000.0 in Q3 2025, with the low at 60227000.0 in Q4 2025.
  • Average Cash from Operations over 4 years is 10265562.5, with a median of 11473500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 657.25% in 2024, then soared 625.37% in 2025.
  • Over 4 years, Cash from Operations stood at 11738000.0 in 2022, then increased by 4.51% to 11209000.0 in 2023, then tumbled by 84.47% to 20677000.0 in 2024, then plummeted by 191.28% to 60227000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 60227000.0, 48455000.0, and 8828000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.